Incuba4.png
Skærmbillede 2014-12-15 kl. 13.14.21.png
mand.i.seng.jpg
Incuba4.png

Intro


Eliminating

Pressure Ulcers

SCROLL DOWN

Intro


Eliminating

Pressure Ulcers

 

Vision

It is the aim for reQbo to eliminate pressure ulcers.

reQbo will prevent ulcers, disability and
isolation of people based on products and
benefits that are scientific recognised.
 
reQbo will support both self-help and care
of the patient, and the patient's conditions.

Patient empowerment, point of care and customer / patient
centricity is simplicity, mobility and flexibility
the core of our products and services.
 
reQbo will thus offer products and services that
saving health services for costly and time consuming
treatments while simplifying and facilitating
health professionals prevention in their daily work.

 
Skærmbillede 2014-12-15 kl. 13.14.21.png

PU categories


Pressure ulcer categories

PU categories


Pressure ulcer categories

 
 

Pressure Ulcers (PU)

are divided into category 1-4.

Grade 1 PU are easily overlooked and can evolve within 1-2 hours. Grade 1 is often only a minor red spot on the sin surface with the PU evolving from within.

Treatment cost factor: 1

Grade 2 In Grade 2 the PU has evolved with a blister, skin-puncture or small sore. Grade 2 accounts for 20% of all treatment costs.

Treatment cost factor: 4

Grade 3 The PU has developed into an open wound with tissues exposed. Severe patient pain and prolonged hospital stay.

Treatment cost factor: 7

Grade 4 Open wound with bones or muscles exposed. Severe patient pain, prolonged hospital stay and fatality.

Treatment cost factor: 10

 
 
mand.i.seng.jpg

Market Pain


Market pains & trends

Market Pain


Market pains & trends

 
 

Market Total addressable market in Europe is approximately 125,000 Hospital and LTC beds, representing a potential revenue more than 632 million $. We expect US to represent at least the same size of total addressable market, so in total more than 1 billion USD.

Market pain PU is highly preventable, but current solutions are ineffective because they lack personalized prevention and dependent highly on healthcare patients still develop PU with a total cost of more than 23 B$ per year. The US Agency for Healthcare Research and Quality estimates that 230 M$ will be saved for every 1% incidence reduction. $ 50.000 is the average PU treatment cost. Global PU prevention device-market estimated at 2.8 B$ by 2020 (5% CAGR).

Market trends Long-term care (LTC) beds are split with 4% in hospitals and 96% in LTC nursing and residential facilities.

Ageing population trend Within hospitals, critical care beds have been reduced in numbers by 3% over the last 10 years. While following the ageing trend of Europeans, the number of beds on LTC facilities has increased 30%.

Data driven Innovation/management Globally, there is a major trend in healthcare towards data-driven, personalized medicine with digital device integration. These solutions are expected to grow in market size over the next decades, as they allow more informed and effective care towards each patient.